Prevalence of Perimyocarditis After Covid-19 Vaccine
- Conditions
- PerimyocarditisCovid19
- Registration Number
- NCT04865900
- Lead Sponsor
- Hillel Yaffe Medical Center
- Brief Summary
The aim of this study is to determine whether there is a higher prevalence of perimyocarditis after undergoing vaccination for Covid-19.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Patients planning Pfizer-BioNTech BNT162b2 vaccination against Covid19
Exclusion Criteria
- Patients infected with Covid19
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Elevated Troponin 4 weeks Laboratory blood tests will be taken before and after Covid19 vaccination and compared. Troponin levels above normal range of 0.4 ng/ml will indicate possibility of perimyocarditis and patient will referred for additional testing.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link SARS-CoV-2 vaccines to perimyocarditis pathogenesis in NCT04865900?
How does incidence of perimyocarditis after mRNA vaccines compare to adenovirus vector vaccines in observational studies?
Which biomarkers correlate with perimyocarditis risk in post-COVID-19 vaccination cohorts using echocardiography and MRI?
What adverse event management strategies are effective for vaccine-induced perimyocarditis in young males?
Are there differences in perimyocarditis prevalence between NCT04865900 and other global post-vaccination surveillance studies?
Trial Locations
- Locations (1)
Hillel Yaffe Medical Center
🇮🇱Hadera, Israel
Hillel Yaffe Medical Center🇮🇱Hadera, Israel